Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea · Delayed Price · Currency is KRW 64,600
+300 (0.47%)
At close: Aug 28, 2026
Hanall Biopharma Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 162,659 | 155,185 | 138,944 | 134,910 | 109,995 | 101,594 |
Revenue Growth | 8.38% | 11.69% | 2.99% | 22.65% | 8.27% | 14.66% |
Gross Profit Gross Profit Growth | 85,739 | 80,775 | 73,206 | 75,040 | 61,876 | 60,231 |
Operating Income Operating Income Growth | 3,924 | -1,611 | 230.47 | 1,743 | 1,506 | 10,099 |
Net Income Net Income Growth | -24,904 | -5,559 | -1,805 | 3,509 | 251.47 | 8,896 |
Earnings Per Share EPS Growth | -481.41 | -109.48 | -35.59 | 69.21 | 4.95 | 173.74 |
EPS Growth | - | - | - | 1298.63% | -97.15% | -55.01% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Export Export Growth | 7,797 | 6,851 | 70.63 | 35.74 | 16.07 |
South Korea South Korea Growth | 147,387 | 132,093 | 134,839 | 109,960 | 101,578 |
Total Total Growth | 155,185 | 138,944 | 134,910 | 109,995 | 101,594 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 30,196 | 24,743 | 24,706 | 56,497 | 53,934 | 80,570 |
Total Debt Total Debt Growth | 44,994 | 31,917 | 1,448 | 1,291 | 1,310 | 1,335 |
Net Cash (Debt) Net Cash Growth | -14,799 | -7,174 | 23,259 | 55,207 | 52,624 | 79,234 |
Net Cash Growth | - | - | -57.87% | 4.91% | -33.59% | -12.11% |
Net Cash Per Share Net Cash Per Share Growth | -286.07 | -141.28 | 458.63 | 1089.06 | 1035.58 | 1547.46 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -9,539 | -2,340 | 9,360 | 29,643 | 25,264 | 839.87 |
Capital Expenditures CapEx Growth | -1,270 | -948 | -1,642 | -2,412 | -2,830 | -4,606 |
Free Cash Flow Free Cash Flow Growth | -10,808 | -3,288 | 7,718 | 27,231 | 22,434 | -3,766 |
Free Cash Flow Growth | - | - | -71.66% | 21.38% | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 52.71% | 52.05% | 52.69% | 55.62% | 56.25% | 59.29% |
Operating Margin | 2.41% | -1.04% | 0.17% | 1.29% | 1.37% | 9.94% |
Pretax Margin | -17.06% | -3.98% | -0.13% | 2.37% | 1.75% | 8.57% |
Profit Margin | -15.31% | -3.58% | -1.30% | 2.60% | 0.23% | 8.76% |
FCF Margin | -6.64% | -2.12% | 5.56% | 20.18% | 20.39% | -3.71% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 640.06 | 3588.03 | 121.16 |
Forward PE | - | 293.05 | 117.15 | 261.09 | 112.30 | 65.12 |
P/FCF Ratio | - | - | 253.93 | 82.47 | 40.22 | - |
PS Ratio | 20.17 | 14.32 | 14.11 | 16.65 | 8.20 | 10.61 |